MacroGenics: Fourth Quarter Earnings Overview

MacroGenics Reports Fourth Quarter Financial Results

MacroGenics Inc., headquartered in Rockville, Maryland, announced on Monday that it recorded a net loss of $14.2 million for the fourth quarter.

The company’s loss amounted to 22 cents per share during this period.

These figures were better than what analysts had anticipated. According to a survey by Zacks Investment Research involving four analysts, the consensus was for a loss of 42 cents per share.

MacroGenics, a biopharmaceutical firm, generated $41.2 million in revenue for the quarter, surpassing the $24.1 million forecasted by three analysts polled by Zacks.

For the full year, MacroGenics reported a total loss of $74.6 million, or $1.18 per share, with annual revenue reaching $149.5 million.